April 28, 2021
HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, today announced that Company’s Management will provide a corporate presentation and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference to be held May 10-13, 2021.
HighTide will present at 8:00am EDT on Thursday, May 13, 2021.
About HighTide Therapeutics
HighTide Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders, with a focus on areas of high unmet medical need and lack of effective treatment options.
HighTide’s lead product candidate, HTD1801, an ionic salt of berberine and ursodeoxycholic acid, is a first-in-class drug new molecular entity being developed for the treatment of primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC). HTD1801 has received Fast Track designation from the U.S. FDA for bothPSCand NASH, as well as Orphan Drug designation for PSC.